title: Open, randomized multicenter comparative trial of rabeprazole, ofloxacin and amoxicillin therapy for Helicobacter pylori eradication: 7 vs. 14 day treatment.
abstract: BACKGROUND
  Because of the increasing resistance to clarithromycin and metronidazole, two of the antibiotics used for the eradication of Helicobacter pylori, new therapeutic alternatives are needed. The aim of this study was to determine the efficacy of a randomized, comparative trial of 7 vs. 14-day triple treatment with rabeprazole, ofloxacin and amoxicillin for H. pylori eradication.
  
  
  METHODS
  The present authors studied 76 dyspeptic patients infected with H. pylori diagnosed by both histology and a rapid urease test. Patients were randomized to receive rabeprazole (20 mg b.i.d.), plus ofloxacin (400 mg b.i.d.) and amoxicillin (1000 mg b.i.d.) for 7 days (group 1) vs. 14 days (group 2) and were followed by 6 weeks. Eradication was assessed 4 weeks after completing the course of study treatment by the (14)C-urea breath test. Per protocol and intention-to-treat eradication rates were determined.
  
  
  RESULTS
  For the intention to treat analysis, the eradication rate was 62.2% for group 1 and 92.3% for group 2 (p =.004). For the per protocol analysis, eradication rate for group 1 was 63.9% and for group 2 was 97.3% (p =.001).
  
  
  CONCLUSIONS
  Triple therapy with rabeprazole, amoxicillin and ofloxacin by 14 days was efficient for H. pylori eradication and therefore deserves further study. The same regimen prescribed for 7 days had a significantly lower and unacceptable cure rate and should not be used.
authors.affiliation: Servicio de Gastroenterología, Hospital Universitario Dr José Eleuterio González Universidad Autónoma de Nuevo León, Mexico. fbosques58@hotmail.com
authors.forename: Francisco J
authors.initials: FJ
authors.lastname: Bosques-Padilla
authors.forename: Elvira
authors.initials: E
authors.lastname: Garza-González
authors.forename: Irma E
authors.initials: IE
authors.lastname: Calderón-Lozano
authors.forename: Gerardo
authors.initials: G
authors.lastname: Reed-SanRoman
authors.forename: Mauricio
authors.initials: M
authors.lastname: de Ariño Suárez
authors.forename: Miguel A
authors.initials: MA
authors.lastname: Valdovinos-Díaz
authors.forename: Antonio
authors.initials: A
authors.lastname: Orozco-Gámiz
authors.forename: Juan M
authors.initials: JM
authors.lastname: Blancas-Valencia
authors.forename: José L
authors.initials: JL
authors.lastname: Tamayo-de la Cuesta
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000658:Amoxicillin / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000382:microbiology; D016480:Helicobacter pylori / Q000302:isolation & purification* / Q000378:metabolism; D006801:Humans; D008297:Male; D008800:Mexico; D008875:Middle Aged; D015242:Ofloxacin / Q000627:therapeutic use*; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D064750:Rabeprazole; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D064750:Rabeprazole; D000658:Amoxicillin; D015242:Ofloxacin; D009853:Omeprazole